The Biotech Growth Trust PLC (LON:BIOG) has announced its Fact Sheet as at 30 June 2026.
Commentary
In June, the NAV per share was +19.2%, the share price was +20.6% and the benchmark NASDAQ Biotechnology Index (net, total return, sterling adjusted) was +11.4%.
During June, the Company outperformed while broader markets were modestly lower. Investor attention shifted during the month, as renewed scrutiny of the return on AIrelated capital spending drove a rotation out of companies with high capital spending and back into areas of the market that had lagged, including biotech. Interest rate headwinds persisted but were outweighed by improving sentiment and positive momentum within the biotech sector.
June was a busy month for the sector. Major medical meetings, including the American Society of Clinical Oncology (ASCO) and the American Diabetes Association (ADA), took place early in the month and provided a catalyst-rich backdrop for healthcare investors. Attention then shifted to regulatory developments, as the FDA reversed its position and told uniQure that, contrary to the agency’s most recent opinion that the company’s existing data were insufficient for filing its gene therapy for Huntington’s disease, the company could file an application without needing to conduct an additional
trial. This reversal was viewed as a sign of a potentially more constructive review environment
Biotech Growth Trust plc (LON:BIOG) seeks capital appreciation through investment in the worldwide biotechnology industry. The Company and the Company’s Portfolio Manager believe that there is a high congruence between companies that seek to act responsibly and those that succeed in building long-term shareholder value.
